Published on March 21, 2024, in the Journal of Clinical Oncology, the PACE trial explored whether continuing CDK4/6 inhibitors (CDK4/6i) with endocrine therapy beyond progression could benefit patients with hormone receptor-positive/HER2-negative metastatic breast cancer (MBC). It also assessed the impact of adding a checkpoint inhibitor.
The phase II trial enrolled 220 patients and compared fulvestrant (F), fulvestrant plus palbociclib (F + P), and fulvestrant plus palbociclib with avelumab (F + P + A). While F + P did not significantly improve progression-free survival (PFS) versus fulvestrant alone (4.6 vs. 4.8 months), adding avelumab increased PFS to 8.1 months, particularly in patients with ESR1 and PIK3CA alterations.
These findings suggest immunotherapy combinations may hold promise in HR+/HER2– MBC.
Special thanks to the research team for this important contribution to breast cancer research.
For more information, check out the full study: https://lnkd.in/eermhg2j
